155 related articles for article (PubMed ID: 36881367)
41. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
[TBL] [Abstract][Full Text] [Related]
42. Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study.
Ren L; Li L; Zhang L; Li X; Fu X; Wang X; Wu J; Sun Z; Feng X; Chang Y; Zhou Z; Nan F; Yan J; Kong F; Zhang M
Indian J Hematol Blood Transfus; 2022 Jan; 38(1):42-50. PubMed ID: 35115740
[TBL] [Abstract][Full Text] [Related]
43. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.
Zhang JP; Lee EQ; Nayak L; Doherty L; Kesari S; Muzikansky A; Norden AD; Chen H; Wen PY; Drappatz J
J Neurooncol; 2013 Oct; 115(1):71-7. PubMed ID: 23828279
[TBL] [Abstract][Full Text] [Related]
44. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
45. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
Steffanoni S; Batchelor TT
Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
[TBL] [Abstract][Full Text] [Related]
46. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
Schaff L; Nayak L; Grommes C
Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38597202
[TBL] [Abstract][Full Text] [Related]
47. Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy.
Khimani NB; Ng AK; Chen YH; Catalano P; Silver B; Mauch PM
Ann Oncol; 2011 Apr; 22(4):979-984. PubMed ID: 20935059
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
Lionakis MS; Dunleavy K; Roschewski M; Widemann BC; Butman JA; Schmitz R; Yang Y; Cole DE; Melani C; Higham CS; Desai JV; Ceribelli M; Chen L; Thomas CJ; Little RF; Gea-Banacloche J; Bhaumik S; Stetler-Stevenson M; Pittaluga S; Jaffe ES; Heiss J; Lucas N; Steinberg SM; Staudt LM; Wilson WH
Cancer Cell; 2017 Jun; 31(6):833-843.e5. PubMed ID: 28552327
[TBL] [Abstract][Full Text] [Related]
49. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
[TBL] [Abstract][Full Text] [Related]
50. Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma.
Yang Y; Li Q; Ma J; Kang H; Lin Z; Wang Y; Ma Y; Chen B
Front Oncol; 2023; 13():1098785. PubMed ID: 37182159
[TBL] [Abstract][Full Text] [Related]
51. Ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the "RTL" (regional Tuscan lymphoma network).
Cencini E; Mecacci B; Morelli F; Ghio F; Romano I; Birtolo S; Simonetti F; Zoi V; Moretti S; Sant'Antonio E; Cuccaro A; Santini S; Kovalchuk S; Galimberti S; Bocchia M; Fabbri A
Am J Blood Res; 2021; 11(4):373-383. PubMed ID: 34540345
[TBL] [Abstract][Full Text] [Related]
52. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
Chen T; Liu Y; Wang Y; Chang Q; Wu J; Wang Z; Geng D; Yu JT; Li Y; Li XQ; Chen H; Zhuang D; Li J; Wang B; Jiang T; Lyu L; Song Y; Qiu X; Li W; Lin S; Zhang X; Lu D; Lei J; Chen Y; Mao Y
J Hematol Oncol; 2022 Sep; 15(1):136. PubMed ID: 36176002
[TBL] [Abstract][Full Text] [Related]
53. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
Patrij K; Reiser M; Wätzel L; Pels H; Kowoll A; Herrlinger U; Engert A; Linnebank M; Schackert G; Vogt-Schaden M; Egerer G; Lamprecht M; Batchelor TT; Schlegel U; Schmidt-Wolf IG;
Ger Med Sci; 2011; 9():Doc11. PubMed ID: 21698087
[TBL] [Abstract][Full Text] [Related]
54. Genomic characterization of primary central nervous system lymphoma.
Fukumura K; Kawazu M; Kojima S; Ueno T; Sai E; Soda M; Ueda H; Yasuda T; Yamaguchi H; Lee J; Shishido-Hara Y; Sasaki A; Shirahata M; Mishima K; Ichimura K; Mukasa A; Narita Y; Saito N; Aburatani H; Nishikawa R; Nagane M; Mano H
Acta Neuropathol; 2016 Jun; 131(6):865-75. PubMed ID: 26757737
[TBL] [Abstract][Full Text] [Related]
55. Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Zhang Y; Liu P; Cai J; Jing H; Zou L; Huang H; Wu Y; Li W; Zhong L; Jin X; Ye X; Feng R; Zhang H; Zhang L; Lin L; Sun X; Tian Y; Xia Z; Li Z; Huang H; Xia Y; Cai Q
Cancer Med; 2022 Nov; 11(22):4134-4145. PubMed ID: 35438258
[TBL] [Abstract][Full Text] [Related]
56. Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.
Houillier C; Chabrot CM; Moles-Moreau MP; Willems L; Ahle G; Waultier-Rascalou A; Fornecker LM; Hoang-Xuan K; Soussain C
Neurology; 2021 Sep; 97(13):628-631. PubMed ID: 34580183
[TBL] [Abstract][Full Text] [Related]
57. Targets and treatments in primary CNS lymphoma.
von Roemeling C; Ferreri AJM; Soussain C; Tun HW; Grommes C
Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38659230
[TBL] [Abstract][Full Text] [Related]
58. Outcomes of Autologous Stem Cell Transplantation as a Consolidative Strategy for the Treatment of Primary and Isolated Secondary Central Nervous System Diffuse Large B Cell Lymphomas.
Sahin U; Gokmen A; Soydan E; Urlu SM; Merter M; Gokgoz Z; Arslan O; Ozcan M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e1-e13. PubMed ID: 36344419
[TBL] [Abstract][Full Text] [Related]
59. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.
Hou K; Yu Z; Jia Y; Fang H; Shao S; Huang L; Feng Y
Crit Rev Oncol Hematol; 2020 Aug; 152():103010. PubMed ID: 32540781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
